You need to learn to take criticism in a mature way instead of lashing out at the messenger and then attempting to hide further shortcomings with lame humor.
In the meantime please request that your esteemed board members of all 4 of your world renowned and highly acclaimed boards review this study in order to debunk or confer legitimacy to the findings.
https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1.full.pdf
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity:
reinfections versus breakthrough infections
Sivan Gazit, MD MA1,2*; Roei Shlezinger, BA1; Galit Perez, MN MA2; Roni Lotan,
PhD2; Asaf Peretz, MD1,3; Amir Ben-Tov, MD1,4; Dani Cohen, PhD4; Khitam
Muhsen, PhD4; Gabriel Chodick, PhD MHA2,4; Tal Patalon, MD1,2
*Corresponding author.
1Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare
Services, Tel Aviv, 68125, Israel.
2 Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services,
Israel.
3Internal Medicine COVID-19 Ward, Samson Assuta Ashdod University Hospital,
Ashdod Israel.
4Sackler Faculty of Medicine, School of Public Health, Tel Aviv University, Tel
Aviv, Israel.
The authors declare they have no conflict of interest.
Funding: There was no external funding for the project.
Corresponding author: Sivan Gazit,
[email protected], 27 HaMared street, Tel Aviv,
68125, Israel
All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprintthis version posted August 25, 2021. ;
https://doi.org/10.1101/2021.08.24.21262415doi: medRxiv preprint
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract
Background:
Reports of waning vaccine-induced immunity against COVID-19 have begun to
surface. With that, the comparable long-term protection conferred by previous
infection with SARS-CoV-2 remains unclear.
Methods:
We conducted a retrospective observational study comparing three groups: (1)SARS-
CoV-2-naïve individuals who received a two-dose regimen of the BioNTech/Pfizer
mRNA BNT162b2 vaccine, (2)previously infected individuals who have not been
vaccinated, and (3)previously infected and single dose vaccinated individuals. Three
multivariate logistic regression models were applied. In all models we evaluated four
outcomes: SARS-CoV-2 infection, symptomatic disease, COVID-19-related
hospitalization and death. The follow-up period of June 1 to August 14, 2021, when
the Delta variant was dominant in Israel.
Results:
SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk
for breakthrough infection with the Delta variant compared to those previously
infected, when the first event (infection or vaccination) occurred during January and
February of 2021. The increased risk was significant (P<0.001) for symptomatic
disease as well. When allowing the infection to occur at any time before vaccination
(from March 2020 to February 2021), evidence of waning natural immunity was
demonstrated, though SARS-CoV-2 naïve vaccinees had a 5.96-fold (95% CI, 4.85 to
7.33) increased risk for breakthrough infection and a 7.13-fold (95% CI, 5.51 to 9.21)
increased risk for symptomatic disease. SARS-CoV-2-naïve vaccinees were also at a
greater risk for COVID-19-related-hospitalizations compared to those that were
previously infected.
Conclusions:
This study demonstrated that natural immunity confers longer lasting and stronger
protection against infection, symptomatic disease and hospitalization caused by the
Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced
immunity. Individuals who were both previously infected with SARS-CoV-2 and
given a single dose of the vaccine gained additional protection against the Delta
variant.
